← Leaderboards
Djamel Lebeche
Massachusetts General Hospital
$7,694,093
Attributed
$8,159,075
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,159,075 · 8
By mechanism
R01$6,527,372 · 4
K01$676,350 · 1
R21$470,853 · 1
R43$315,000 · 1
R56$169,500 · 1
Top collaborators
- Mohamed Trebak2 shared
- Tauheed Ishrat1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Thomas Force$10,984,600
- Karen L. Furie$5,939,373
- Eng H. Lo$32,456,318
- Bradley T Hyman$51,936,441
- David E Sosnovik$15,139,691
Others in their field
Top investigators on “Animal Model”
- David Heimbrook · Leidos Biomedical Research, Inc.$464,525,875
- Dennis R. Burton · Scripps Research Institute$204,129,233
- Joseph E Robertson · Oregon Health & Science University$126,125,279
- Peter Gordon Gillespie · Oregon Health And Science University$105,808,119
- David M Anderson · University Of Washington$102,920,737
- Polly Chang · Sri International$84,271,267
Research focus
Animal ModelIn VivoDiabetes MellitusCalciumPhysiologicalDefectHomeostasisMetabolismDiabeticInsulin ResistanceMetabolicAnimalsInsulinLeadHeart FailurePathway InteractionsObesityResponseCardiacBaseMolecularFunctional DisorderNovel StrategiesLoss Of Function
Grant awards (25)
Novel Pharmacological Approach to Stroke Neuroprotection$459,111
R01 · FY2025 · NS · contact PI
Targeting Diabetes With Novel SERCA Allosteric Activators$346,500
R01 · FY2022 · DK · contact PI
Targeting Diabetes With Novel SERCA Allosteric Activators$381,375
R01 · FY2021 · DK · contact PI
Molecular and Metabolic phenotype of Impaired AdipoR1 in the Heart$423,750
R01 · FY2020 · HL · contact PI
Targeting Diabetes With Novel SERCA Allosteric Activators$381,375
R01 · FY2020 · DK · contact PI
Molecular and Metabolic phenotype of Impaired AdipoR1 in the Heart$423,750
R01 · FY2019 · HL · contact PI
Targeting Diabetes With Novel SERCA Allosteric Activators$381,375
R01 · FY2019 · DK · contact PI
Molecular and Metabolic phenotype of Impaired AdipoR1 in the Heart$423,750
R01 · FY2018 · HL · contact PI
Targeting Diabetes With Novel SERCA Allosteric Activators$423,750
R01 · FY2018 · DK · contact PI
Targeting Diabetes With Novel SERCA Allosteric Activators$381,375
R01 · FY2018 · DK · contact PI
Developing Small Molecule Therapies for Heart Failure$315,000
R43 · FY2018 · HL · contact PI
Molecular and Metabolic phenotype of Impaired AdipoR1 in the Heart$423,750
R01 · FY2017 · HL · contact PI
Genes and miRNAs controlled by ORAI3 in cardiovascular remodeling$207,277
R21 · FY2017 · AG · contact PI
Genes and miRNAs controlled by ORAI3 in cardiovascular remodeling$263,576
R21 · FY2016 · AG · contact PI
Targeting Diabetes With Novel Small Molecule Therapeutics$169,500
R56 · FY2015 · DK · contact PI
Genetic Analysis of microRNAs Function in Diabetic Cardiomyopathy$411,122
R01 · FY2014 · HL · contact PI
Genetic Analysis of microRNAs Function in Diabetic Cardiomyopathy$399,376
R01 · FY2013 · HL · contact PI
Genetic Analysis of microRNAs Function in Diabetic Cardiomyopathy$419,513
R01 · FY2012 · HL · contact PI
Genetic Analysis of microRNAs Function in Diabetic Cardiomyopathy$423,750
R01 · FY2011 · HL · contact PI
Genetic Analysis of microRNAs Function in Diabetic Cardiomyopathy$423,750
R01 · FY2010 · HL · contact PI
Electrical Remodeling and Cardiac Hypertrophy and Signaling$135,270
K01 · FY2008 · HL · contact PI
Electrical Remodeling and Cardiac Hypertrophy and Signaling$135,270
K01 · FY2007 · HL · contact PI
Electrical Remodeling and Cardiac Hypertrophy and Signa*$135,270
K01 · FY2006 · HL · contact PI
Electrical Remodeling and Cardiac Hypertrophy and Signa*$135,270
K01 · FY2005 · HL
Electrical Remodeling and Cardiac Hypertrophy and Signal$135,270
K01 · FY2004 · HL